

JOSH GREEN, M.D.
GOVERNOR
KE KIA'ĀINA



RYAN YAMANE
DIRECTOR
KA LUNA HO'ŌKELE

JOSEPH CAMPOS II
DEPUTY DIRECTOR
KA HOPE LUNA HO'ŌKELE

STATE OF HAWAII
KA MOKU'ĀINA O HAWAI'I
DEPARTMENT OF HUMAN SERVICES
KA 'OIHANA MĀLAMA LAWELAWĒ KANAKA
Med-QUEST Division
Clinical Standards Office
P.O. Box 700190
Kapolei, Hawai'i 96709-0190

TRISTA SPEER
DEPUTY DIRECTOR
KA HOPE LUNA HO'ŌKELE

MINUTES OF REMOTE MEETING
Med-QUEST Drug Use Review (DUR) Board

Date: Wednesday, August 14, 2024

Time: 12:00 P.M. (Noon)

Remote Meeting Location: Zoom Meeting participation for members and the public:
<https://medquest-hawaii-gov.zoom.us/j/83814701914?pwd=GYd8f0EZxMGhFcP8udsNf0p7fXew00.1>

In-Person Location:
Kakuhihewa Building
Conference Rooms 577A and 577B
601 Kamokila Blvd., Kapolei, Hawaii 96707

Members Present:

Dr. James Lumeng, Chair, Physician
Wendell Au, Vice-Chair, Pharmacist
Eddie Fox, Medical Service Representative
Kathleen T. Kang-Kaulupali, Pharmacist
Miki Lei Morita, Pharmacist
Reed Muraoka, Pharmacist
Dr. Curtis Toma, Physician
Dr. Greg Yuen, Physician

Members Absent:

None

Staff present:

Erin Gomez, Clinical Standards Office (CSO) Office Assistant
Erin Lau, District Attorney General (DAG)
Julie Jay, CSO Administrative Assistant
Kathleen T. Kang-Kaulupali, CSO DUR Coordinator, Pharmacist

MINUTES OF REMOTE MEETING
Med-QUEST Drug Use Review (DUR) Board
August 14, 2024

Michael Mau, Information Technology Specialist
Dr. Curtis Toma, CSO Medical Director

Public guests: Gary Peton, Dr. Lynette Honbo, Patrick Uyemoto (Novo Nordisk), Ann Nelson (Vertex Pharmaceuticals), Chad Duncan (Vertex Pharmaceuticals), ARTIA Solutions, Stephanie Abraham, Linda Finch (Biogen), Alfred Herrera, Mike Donabedian (Sarepta Therapeutics), and KITV4 News.

- I. Vice-Chair Wendel Au called the meeting to order at 12:05 pm and welcomed participants to the meeting. He proceeded with a roll call of DUR Board members. Quorum was established with 7 members present. Introductions of the new Clinical Standards Office Administrator Ranjani Starr and the prospective DUR Board member Kelsey Trujillo were presented. The Board members participating were informed to declare if they were not alone. Each participating Board members declared that they were alone. Other guests of the Drug Use Review Board were noted and declared that they were alone: Gary Peton, Conduent Government Healthcare, pharmacist (present) and Dr. Lynette Honbo, Conduent Government Healthcare, Medical Consultant (present).
- II. The May 8, 2024, meeting minutes were reviewed by the Board. (Dr. James Lumeng joined the meeting.) There was no public testimony. Without further discussion, it was moved to accept the minutes as presented and the motion was seconded. The motion passed unanimously, with no opposition and no abstentions.
- III. Old Business (updates) by Kathleen Kang-Kaulupali
 - A. Dental pain medications and benzodiazepines review will be ongoing and reported if outliers are identified.
 - B. Fluoride access for children is improving and the review is completed.
 - C. State of Hawai'i Organ and Tissue Transplant (SHOTT): Outreach is to billing provider to verify amount and type of units utilized sill occur. Education and recovery of over-paid claims are the priority. An edit in the point of sale (POS) prospective drug utilization review (proDUR) for the prescription claim processing is the next option if the correct unit and amount are not occurring.
 - D. Naloxone nasal sprays utilization in 2019 versus 2023: By Gary Peton. Zero claims for nasal spray were submitted in 2019 for both Medicaid managed care plans and FFS. (Injections were prescribed instead sprays). Generic nasal spray was available in 2023. Prescribing increased to 600-700 doses per quarter in 2024 per drug rebate data. Overall improved access to naloxone is present for the public from multiple non-Medicaid venues as well.
 - E. No public testimony.

IV. Dental Program

- A. Second quarter 2024 highlights were shared by Gary Peton. The volume of claims paid continues to increase over the previous quarter 2024. No multiple claims per patient and no provider outliers were identified. There are new providers including oral surgeons with increases on neighbor islands. Eddie Fox asked if any issues with quantities occurred. Gary Peton replied that there was no issue with the prescribed quantities or the existing formulary quantity limits. The average claim spend is like last year: Approximately \$20/claim, half dispensing fee and half drug cost.
- B. Controlled drugs utilization for Calendar Year 2023 was presented by Kathleen Kang-Kaulupali.
- i. No outlier providers were identified.
 - ii. For 2024 the U.S. Centers for Disease Control (CDC) and Prevention Dental Pain guidelines has no updates and cites CDC 2022 guidelines. 2023-2024 American Dental Association (ADA) Dental Pain Guidelines recommend nonopioid medications are first-line therapy for managing acute dental pain after tooth extraction(s) and the temporary management of toothache. The use of opioids should be reserved for clinical situations when the first-line therapy is insufficient to reduce pain or there is contraindication of nonsteroidal anti-inflammatory drugs. Clinicians should avoid the routine use of just-in-case prescribing of opioids and should exert extreme caution when prescribing opioids to adolescents and young adults. Miki Morita shared local dental prescribing does include antibiotic, nonsteroidal anti-inflammatory and controlled substance pain medication.
 - iii. The Hawaii Revised Statute §329-38.2 repealed June 30, 2023, no longer provides exclusions from checking the prescription drug monitoring program (PDMP) before prescribing a controlled drug. Previously excluded were controlled substances prescribed from an emergency room, for acute and less than 3-day supply without refill, treating post-operative pain less than or equal to a 3-day supply with no refills, terminal disease receiving hospice or palliative care or the PDMP is non-functional. All controlled dental prescriptions are to be checked on the PDMP.
 - iv. The Hawaii Revised Statute §329-38.5 repealed June 30, 2023, required an informed consent process between prescribing provider and qualifying opioid therapy patient, if opioid treatment is greater than 3 months, prescribed benzodiazepine and opioids together, opioids that exceed 90 morphine equivalent doses.
 - v. The SUPPORT Act [Social Security Act Section 1944 (42 USC 1396w-3a)] beginning October 1, 2021, requires each covered provider to check the Patient Drug history through the PDMP. Dr. Lumeng shared that provider

- education is preferred over change in the current controlled drugs formulary or quantity limits.
- vi. No public testimony was shared. No motion was made.
- V. State of Hawai'i Organ and Tissue Transplant (SHOTT) Program was presented by Gary Peton.
- A. Expensive drug claims greater than \$1,000 for the second quarter 2024:
 - 1. No outliers. Dr. Honbo explained that when claims are billed for proper units, the greater than \$25,000 limit is triggered for manual review and authorization. Otherwise, an incorrectly billed claim can be bypassed and not viewed as an outlier. Gary Peton explained that a quantity limit can be placed on the drug to require the correct units processing to payment or else trigger a manual review.
 - 2. Few new oncology drugs and Dr. Honbo shared that all new clinically approved drugs are high in cost.
 - B. Medication profile reviews for Calendar Year 2023:
 - 1. High volume utilizers were seen with antibiotics, antifungals, and immunosuppressant therapies due to the nature of the SHOTT program. Nothing unusual was noted.
 - 2. A high-cost user found to have a \$18,000/month oncology drug for 9 months.
 - 3. High denial of claims occurred for a compounding claim and for Medicare crossover eligibility.
 - i. The compounding pharmacy claim entry was not following established procedures and triggering electronic denials: Manual billing on paper claims is required.
 - ii. Dr. Honbo explained that if a beneficiary does not have Medicare Part D with Part B, the crossover claim will be denied.
 - C. There was no public testimony on New Business. No motion was made.
- VI. U.S. Centers for Medicare and Medicaid Annual Drug Use Review Survey: Prescription Drug Monitoring Program reports will be refined. The vendor is not able to produce needed data for Hawaii or for many states.
- VII. The next DUR Board Meeting is Wednesday, November 20, 2024. There was no public testimony. Without further discussion, it was moved to adjourn the meeting by Wendel Au and seconded by Eddie Fox. The motion passed unanimously with no opposition and no abstentions. The meeting was adjourned at 12:57 pm.